Therapeutic Solutions International Company Description
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States.
The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health.
Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production.
It also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract.
In addition, the company develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology; and portfolio of immunotherapies that provides dendritic cell vaccines for cancers to Parkinson’s disease developed on StemVacs platform.
Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Timothy Dixon |
Contact Details
Address: 701 Wild Rose Lane Elk City, Nevada 83525 United States | |
| Phone | 760 295 7208 |
| Website | therapeuticsolutionsint.com |
Stock Details
| Ticker Symbol | TSOI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US8833781011 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy George Dixon | Chairman, Chief Executive Officer, President and Chief Financial Officer |
| Dr. Feng Lin M.D., Ph.D. | Chief Scientific Officer |
| Dr. James Drew Veltmeyer M.D. | Chief Medical Officer, Vice Chairman of CTE Advisory Board and Member of Scientific Advisory Board |
| Famela Ramos | Vice President of Business Development |
| Serena Robella | Director of Sales |